Issuer state, before the event · financials as of 2026-09-08
Boston Scientific
Profile
- CIK
- 0000885725
- SIC
- 3841
- Sector (engine map)
- Pharma and devices Derived
- Reportable segments
- 2 Verified
- Fiscal period
- FY2025
- Financials as of
- last 10-K before 2026-09-08
- Ratio table
- Standard (default) internal calibration
Source documents
- XBRL company facts0000885725-26-000010
- Form 10-K FY20250000885725-26-000010
- Form 8-K Item 1.052026-09-08
Financial context, FY2025 (USD m)
As-reported proxies. S&P adjustments not applied.
DerivedVerifiedNeeds analyst input
| Metric | USD m | Provenance | XBRL tags or formula |
|---|---|---|---|
| EBITDA | 4,981Derived | Derived | OperatingIncomeLoss + DepreciationDepletionAndAmortization |
| Debt | 11,436Derived | Derived | DebtCurrent + LongTermDebtAndCapitalLeaseObligations |
| FFO | 4,101Derived | Derived | OperatingIncomeLoss + DepreciationDepletionAndAmortization + InterestPaidNet + IncomeTaxesPaidNet |
| CFO | 4,534Verified | Verified | NetCashProvidedByUsedInOperatingActivities |
| FOCF | 3,658Derived | Derived | NetCashProvidedByUsedInOperatingActivities + PaymentsToAcquirePropertyPlantAndEquipment |
| DCF | Needs analyst input | Derived | NetCashProvidedByUsedInOperatingActivities + PaymentsToAcquirePropertyPlantAndEquipmentmissing: dividends_paid, share_repurchases |
| Cash interest | 319Verified | Verified | InterestPaidNet |
| Operating leases (shown separately) | 536Verified | Verified | OperatingLeaseLiability |
Core ratios against S&P published bands
standard volatility table. Bands shown by numeric range.
FFO to debt35.9%Verifiedpre-event
In the 30% to 45% range. 19.5% above the next weaker boundary (30%), so not borderline.
Debt to EBITDA2.30xVerifiedpre-event
In the 2x to 3x range. 23.5% below the next weaker boundary (3x), so not borderline.
Pre-eventWithin 10% of a band boundary